Navigation Links
Meningococcal Disease in Burkina Faso

From 1 January to 31 January 2007, the Ministry of Health reported 789 suspected cases including 96 deaths (case-fatality rate, 12.2%) in the country. //

Ouargaye district has an attack rate above the epidemic threshold and another three districts, Banfora, Batie and Sapouy are in the alert phase.

Cerebrospinal fluid specimens have tested positive for Neisseria meningitidis serogroup A by latex test.

The Ministry of Health is planning to conduct a vaccination campaign in Ouargaye this week.

Source-Bio-Bio Technology
SRI
'"/>




Page: 1

Related medicine news :

1. Possibility Of A Meningococcal Outbreak In NSW
2. Meningococcal Scare in Queensland
3. Meningococcal-B Vaccine Greatly Reduces The Risk of The Disease
4. Vaccine For Meningococcal Disease Trialled In Western Australia
5. Meningococcal Disease In Uganda
6. Meningococcal Disease in Sudan
7. More Research on Meningococcal Infection Called for
8. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
9. Vitamins-The answer to Heart Disease?
10. Link between Constipation and Parkinsons Disease
11. Levels Of Blood Proteins May Help Heart Disease Care
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Meningococcal Disease Burkina Faso

Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10BioCryst Provides Update Regarding Peramivir for Influenza 5116 1BioCryst Provides Update Regarding Peramivir for Influenza 5116 2BioCryst Provides Update Regarding Peramivir for Influenza 5116 3BioCryst Provides Update Regarding Peramivir for Influenza 5116 4BioCryst Provides Update Regarding Peramivir for Influenza 5116 5Study explores how life experiences contribute to the biological changes of Alzheimers 10197 1Study explores how life experiences contribute to the biological changes of Alzheimers 10197 2Study explores how life experiences contribute to the biological changes of Alzheimers 10197 3Doctor Visits Are Getting Short Shrift in Tight Economy 58589 1Doctor Visits Are Getting Short Shrift in Tight Economy 58589 2